Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series.
Journal of Psychiatric Practice July 1, 2023 Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli et al.
Background: Cognitive symptoms are a core feature of depressive disorders, interfere with full functional recovery and are prominent in patients with treatment-resistant depression (TRD), particularly in severe chronic cases. Intranasal (IN) esketamine was recently approved for the treatment of TRD; however, its effects on cognitive symptoms are unclear. In this article, we describe cognitive...
DOI: 10.1097/pra.0000000000000723 (opens in new tab)
Ketamine
Depression
Humans
Antidepressive agents
+3